CATALENT, INC.

(CTLT)
  Report
Real-time Estimate Cboe BZX  -  05/25 02:31:29 pm EDT
96.56 USD   -0.21%
05/20Catalent Invests $175 Million to Expand Manufacturing Capabilities and Capacity at Winchester, Kentucky
AQ
05/17Catalent Launches UpTempo Virtuoso AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic
AQ
05/11TRANSCRIPT : Catalent, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 12:40 PM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Catalent : Launches New Xpress Pharmaceutics™ Service to Expedite Development of Oral Drugs for Adaptive Phase 1 Clinical Trials

01/18/2022 | 09:20am EDT

SOMERSET, N.J. - January 18, 2022 - Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the launch of its new Xpress Pharmaceutics™ service, designed to accelerate the development of oral drugs through Phase 1 clinical studies. By integrating formulation development, on-demand clinical manufacturing, regulatory support and clinical testing, the approach can reduce both the cost and time taken to complete first-in-human trials.

Xpress Pharmaceutics allows Catalent to work alongside innovator and clinical research organizations, and provide formulated clinical trial material with the necessary stability data that can be prepared for dosing patients at the clinical site, in line with adaptive study protocols. This approach provides a faster alternative to the traditional clinical development model, and offers the advantage of flexible dose and/or formulation composition adjustment during a clinical trial, guided by real-time clinical data.

"Achieving early clinical success milestones as fast as possible is crucial in modern drug development, especially for emerging innovators, and this new service combines Catalent's core expertise in drug formulation with manufacturing, analytics, and regulatory expertise, to design better drugs for use in adaptive trials," said Jonathan Arnold, President, Oral and Specialty Delivery at Catalent. "By focusing on the areas that are crucial for fast progression to, and through, Phase 1 trials, Xpress Pharmaceutics can potentially halve the time to complete studies."

The service will be delivered by formulation development experts at Catalent's facilities in Nottingham, U.K., and Beinheim, France, and supported by the company's global Regulatory Affairs team. To further support accelerated timelines, Catalent has a pre-qualified clinical research organization partner, allowing seamless transition from manufacturing into clinical testing.

ABOUT CATALENT

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.

With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually.

Catalent's expert workforce exceeds 18,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™

Disclaimer

Catalent Inc. published this content on 18 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 January 2022 14:19:08 UTC.


© Publicnow 2022
All news about CATALENT, INC.
05/20Catalent Invests $175 Million to Expand Manufacturing Capabilities and Capacity at Winc..
AQ
05/17Catalent Launches UpTempo Virtuoso AAV Platform to Reduce Gene Therapy Development Time..
AQ
05/11TRANSCRIPT : Catalent, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11..
CI
05/04Morgan Stanley Adjusts Catalent's Price Target to $132 from $145, Keeps Overweight Rati..
MT
05/04UBS Adjusts Catalent Price Target to $145 From $155, Maintains Buy Rating
MT
05/04KeyBanc Adjusts Catalent's Price Target to $125 From $155, Keeps Overweight Rating
MT
05/03SECTOR UPDATE : Health Care Stocks Rise on Tuesday
MT
05/03SECTOR UPDATE : Health Care Advance Led Higher by Biotechs
MT
05/03SECTOR UPDATE : Health Care Stocks Advancing on Tuesday, Led Higher by Biotechs
MT
05/03SECTOR UPDATE : Health Care
MT
More news
Analyst Recommendations on CATALENT, INC.
More recommendations
Financials (USD)
Sales 2022 4 857 M - -
Net income 2022 481 M - -
Net Debt 2022 3 136 M - -
P/E ratio 2022 35,9x
Yield 2022 -
Capitalization 17 341 M 17 341 M -
EV / Sales 2022 4,22x
EV / Sales 2023 3,81x
Nbr of Employees 17 300
Free-Float 99,7%
Chart CATALENT, INC.
Duration : Period :
Catalent, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALENT, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 96,76 $
Average target price 134,92 $
Spread / Average Target 39,4%
EPS Revisions
Managers and Directors
John R. Chiminski Chairman & Chief Executive Officer
Alessandro Maselli Vice President-Operations
Thomas P. Castellano Chief Financial Officer & Senior Vice President
Kay Schmidt Senior Vice President-Technical Operations
Julien Meissonnier Chief Scientific Officer & Vice President
Sector and Competitors
1st jan.Capi. (M$)
CATALENT, INC.-24.42%17 341
JOHNSON & JOHNSON6.04%477 336
PFIZER, INC.-9.55%299 678
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494